Virtuální posterová sekce

Kliknutím rozbalíte poster.

P01

IDENTIFICATION OF MOLECULAR MECHANISMS RESPONSIBLE FOR THE DEVELOPMENT OF EXTRAMEDULLARY DISEASE IN MYELOMA AND POTENTIAL NOVEL THERAPEUTIC TARGETS USING TRANSCRIPTOMIC AND EXOME PROFILING

Žihala D. (Ostrava) a spol.

P02

A PHASE lb, OPEN-LABEL, RANDOMIZED STUDY TO ASSESS SAFETY AND PRELIMINARY EFFICACY OF TAFASITAMAB (MOR208) OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA: ANALYSIS OF THE SAFETY RUN-IN PHASE

Belada D. (Hradec Králové) a spol.

P03

CLONAL HEMATOPOIESIS WITH SOMATIC MUTATIONS IN „AYA“ GENERATION OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA

Koblihová J. (Praha) a spol.

P04

ANTI-ANGIOGENIC THERAPY WITH BEVACIZUMAB IS EFFECTIVE IN VIVO IN IBRUTINIB-RESISTANT MANTLE CELL LYMPHOMA

Vočková P. (Praha) a spol.

P06

HOW TO TREAT ELDERLY PATIENTS OVER 80 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA: ALL BENEFIT FROM RITUXIMAB AND SELECTED ONES FROM R-CHOP

Vodička P. (Praha) a spol.

P07

DO NOT WASTE THE DATA: A PIPELINE FOR EVALUATION OF BCR-ABL1 KINASE DOMAIN MUTATION USING INDIVIDUAL THRESHOLDS

Benešová A. (Praha) a spol.

P08

PROTON RADIOTHERAPY FOR MEDIASTINAL HODGKIN LYMPHOMA: THEORETICAL BACKGROUND AND CLINICAL EXPERIENCE

Dědečková K. (Praha) a spol.

P09

IDENTIFICATION OF PML-RARA, CBFB-MYH11 AND RUNX1-RUNX1T1 GENOMIC FUSION SEQUENCES IS FEASIBLE AND ENABLES NAMBIGUOUSLY INTERPRETABLE AND SENSITIVE MONITORING OF MINIMAL RESIDUAL DISEASE

Lukeš J. (Praha) a spol.

P10

DYNAMIC CHANGES OF INHIBITORY KILLERIMMUNOGLOBULIN-LIKE RECEPTORS ON NK CELLS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN INITIAL STUDY

Jindra P. (Plzeň) a spol.

P11

ACTIVE THROMBIN BOUND TO D-DIMERS AND ITS VALUE: NEW APPROACH TO DIAGNOSIS OF THROMBOSIS?

Štikarová J. (Praha) a spol.

P13

STORAGE OF UV LIGHT AND RIBOFLAVIN TREATED RBC AFTER CRYOPRESERVATION AND RECONSTITUTION IN AS-3 ADDITIVE SOLUTION

Kutac D. (Praha) a spol.

P14

MUTUAL COMPETITION BETWEEN IMATINIB AND CARNITINE INTAKE THROUGH THE OCTN2 TRANSPORTER IN CML AND MUSCULAR CELLS

Burda P. (Praha)

P15

ATYPICAL DELETIONS OF THE LONG ARM OF CHROMOSOME 5 WITH RETAINED COMMONLY DELETED REGIONS (CDR) IN MDS

Zemanova Z. (Praha) a spol.

P16

INDIVIDUAL MOLECULAR RESPONSE EVALUATION ON BOTH DNA AND mRNA BCR-ABL1 LEVEL DIMINISHED DIFFERENCES IN TIME TO MOLECULAR RESPONSE ACHIEVEMENT BETWEEN CML PATIENTS WITH e13a2 vs e14a2 TRANSCRIPT TYPE

Machová Poláková K. (Praha) a spol.

P17

THE PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY WT1 GENE EXPRESSION IN PERIPHERAL BLOOD BEFORE AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN AML PATIENTS

Válková V., Vydra J. (Praha) a spol.

P18

ANALYSIS OF CMV REACTIVATION RISK AFTER T CELL REPLETE HAPLOIDENTICAL AND MATCHED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Čemusová B., Vydra J. (Praha) a spol.

P19

RARE TRANSLOCATIONS IN BONE MARROW CELLS OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

Ransdorfová Š. (Praha) a spol.

P20

LncRNA PROFILING REVEALS THAT THE DEREGULATION OF H19, WT1-AS, TCL6, AND LEF1-AS1 IS ASSOCIATED WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME

Dostálová Merkerová M. (Praha) a spol.

P21

LABORATORY DIAGNOSTICS OF 21 UNRELATED FAMILIES FROM CZECH REPUBLIC WITH DYSFIBRINOGENEMIA AND HYPOFIBRINOGENEMIA

Ceznerová E. (Praha) a spol.

P22

KINETICS OF BONE MARROW BLASTS AND USEFULNESS OF DAY 14 AND DAY 21 ASSESSMENT DURING INDUCTION OF ACUTE MYELOID LEUKEMIA

Ráčil Z. (Praha) a spol.

P23

REZISTENCE NA IMATINIB U CML LINIE K562: EXOSOMY Z REZISTENTNÍCH BUNĚK NESOU SPECIFICKÉ MEMBRÁNOVÉ MARKERY A POMÁHAJÍ PŘEŽÍT SENZITIVNÍM BUŇKÁM

Toman O. (Praha) s spol.

P24

NELFINAVIR INHIBITS THE TCF11/Nrf1-MEDIATED PROTEASOME RECOVERY PATHWAY IN MULTIPLE MYELOMA

Fassmannová D. (Praha) a spol.

P26

FUNCTIONAL ANALYSIS OF NEW VARIANT GP1BA GENE IN INHERITED MACROTROMBOCYTOPENIA

Skalníková M. (Brno) s spol.

P27

HBV AND HCV EPIDEMIOLOGY AMONG NEWLY DIAGNOSED NHL PATIENTS IN REAL WORLD ANALYSIS (NIHIL)

Dlouhá L. (Praha) a spol.

P28

SOMATIC MUTATIONS IN HLA-loci IN PATIENTS WITH MYELOID LEUKEMIA

Půbalová Š. (Praha) a spol.

P29

SÉROVÉ HLADINY VYBRANÝCH CYTOKINŮ U AKUTNÍ LYMFOBLASTICKÉ LEUKEMIE DOSPĚLÝCH A JEJICH SOUVISLOST S PROGNOSTICKÝMI FAKTORY A PŘEŽITÍM

Horáček J.M. (Hradec Králové) a spol.

P30

SEARCHING FOR OTHER TOPICS OF QUALIFICATION PLANS IN THE TRANSPLANT PROGRAM CLINICAL PART – THE ONE CENTER EXPERIENCE

Dobrovolná M. (Praha) a spol.

P31

IMPACT OF FIBRINOGEN POST-TRANSLATIONAL MODIFICATIONS ON ITS STRUCTURE AND FUNCTION

Sovová Ž. (Praha) a spol.

P32

SÉROVÉ HLADINY VYBRANÝCH CYTOKINŮ A SOLUBILNÍCH ADHEZNÍCH MOLEKUL U NOVĚ DIAGNOSTIKOVANÉ AKUTNÍ MYELOIDNÍ LEUKEMIE: SOLUBILNÍ RECEPTOR PRO INTERLEUKIN-2 JE PREDIKTOREM CELKOVÉHO PŘEŽITÍ

Kupsa T. (Hradec Králové) a spol.

P33

VLIV POUŽITÉ METODY IZOLACE DNA NA VÝSLEDNOU KVANTIFIKACI PRO MONITOROVÁNÍ BUNĚČNÉHO CHIMERISMU

Josefusová K. (Praha) a spol.